Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rua BioscienceNZSE:RUA -2.44% EBIT per Share is NZ$-0.01 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 813 Drug Manufacturers companies, Rua Bioscience ranks better than 72.57% on this metric.
Rua Bioscience's EBIT per Share for the
six
months ended in Dec. 2025 was NZ$-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 23.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Rua Bioscience's EBIT per Share or its related term are showing as below:
NZSE:RUA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 16.3 Med: 20.05 Max: 23.8
Current: 23.8
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Rua Bioscience was 23.80% per year. The lowest was 16.30% per year. And the median was 20.05% per year.
NZSE:RUA's 3-Year EBIT Growth Rate is ranked better than 72.57% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NZSE:RUA: 23.80
Rua Bioscience's EBIT for the
six
months ended in Dec. 2025 was NZ$-1.63 Mil.
Rua Bioscience (NZSE:RUA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Rua Bioscience EBIT per Share Related Terms
Rua Bioscience EBIT per Share Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rua Bioscience (NZSE:RUA) has a EBIT per Share of NZ$-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rua Bioscience and its competitors. According to the industry distribution chart, Rua Bioscience ranks #223 out of 813 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Rua Bioscience's EBIT per Share too high?
Rua Bioscience's current EBIT per Share is NZ$-0.01. Based on the distribution chart, Rua Bioscience ranks #223 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Rua Bioscience's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rua Bioscience ranks #223 out of 813 companies for EBIT per Share. This puts Rua Bioscience in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Rua Bioscience and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rua Bioscience's current EBIT per Share is NZ$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current EBIT per Share of NZ$-0.01. The current EBIT per Share is NZ$-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current EBIT per Share is NZ$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
